Gilead Collaborates with EVOQ Therapeutics to Advance Immunotherapies in Rheumatoid Arthritis and Lupus
Shots:
- Through preclinical collaboration and licensing agreement, Gilead has the option to license rights to develop and commercialize products for autoimmune diseases by using EVOQ’s NanoDisc technology
- Under the agreement, EVOQ will receive ~$658.5M incl. upfront, option exercise, and milestone payments across all programs, as well as tiered royalties on product sales
- NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens to restore immune tolerance
Ref: Businesswire | Image: Gilead
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
